Surfing the MASH Tsunami
Episodes
S2-E41.2 - Specialties and Organizations Unite to Fight the NASH Epidemic
14 Aug 2021
Contributed by Lukas
Send a textCo-authors Ken Cusi and Stephen Harrison discuss how the multidisciplinary call to action regarding the coming NASH Epidemic came to be, wh...
S2-E41.1 - SPECIAL FEATURE: Interview with Louise Campbell
13 Aug 2021
Contributed by Lukas
Send a textRoger Green and Louise Campbell discuss some of the key elements of the "Preparing for the NASH Epidemic - a Call to Action" pape...
S2-E41 - Preparing for the NASH Epidemic: Behind a Multidisciplinary Call to Action
12 Aug 2021
Contributed by Lukas
Send a textCo-authors Ken Cusi and Stephen Harrison discuss the multidisciplinary call to action regarding the coming NASH Epidemic, how the first pap...
S2-E40.3 - Discussing Comprehensive Care Models For NAFLD - Metrics, Key Performance Indicators and Improving Management
08 Aug 2021
Contributed by Lukas
Send a textJeff Lazarus and Roger Green discuss the ease of creating valuable metrics in a comprehensive care model, while our three practitioners -- ...
S2-E40.2 - Discussing Comprehensive Care Models For NAFLD - Providers Respond
07 Aug 2021
Contributed by Lukas
Send a textStephen Harrison and Louise Campbell discuss their reactions to the recent paper, "Defining Comprehensive Models of Care for NAFLD.&qu...
S2-E40.1 - Discussing Comprehensive Care Models for NAFLD - Jeff Lazarus Presents Research
07 Aug 2021
Contributed by Lukas
Send a textLead author Jeffrey Lazarus and co-author Jörn Schattenberg join the Surfers to discuss how they developed the care models for their recen...
S2-E40 - Discussing Comprehensive Care Models for NAFLD
05 Aug 2021
Contributed by Lukas
Send a textLead author Jeffrey Lazarus and co-author Jörn Schattenberg join the Surfers to discuss their recent paper, "Defining Comprehensive M...
S2-E39.3 - 20K Celebration Interview With Jörn Schattenberg and Ian Rowe
01 Aug 2021
Contributed by Lukas
Send a textThis week's celebration podcast featured interviews including seven of our favorite Surfers. In this week's conversations, we are...
S2-E39.2 - 20K Celebration Interviews With Stephen Harrison and Naim Alkhouri
31 Jul 2021
Contributed by Lukas
Send a textThis week's celebration podcast featured interviews including seven of our favorite Surfers. In this week's conversations, we are...
S2-E39.1 - 20K celebration Interview with Donna Cryer
31 Jul 2021
Contributed by Lukas
Send a textThis week's celebration podcast featured interviews including seven of our favorite Surfers. In this week's conversations, we are...
S2-E39 - Celebrating Two Milestones for SurfingNASH!
29 Jul 2021
Contributed by Lukas
Send a textSeven of our favorite Surfers join together to celebrate 20,000 Buzzsprout downloads and our one-year anniversary of moving to Buzzsprout.L...
S2-E38.3 - Creating an Ecosystem of Community Physicians To Support Clinical Trials
25 Jul 2021
Contributed by Lukas
Send a textGlobal Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer ...
S2-E38.2 - Building a Culture That Encourages Patient Participation
24 Jul 2021
Contributed by Lukas
Send a textGlobal Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer ...
S2-E38.1 - Motivating Underserved Patients to Participate in Clinical Trials
24 Jul 2021
Contributed by Lukas
Send a textGlobal Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer ...
S2-E38 - Increasing Diversity in the Clinical Trial Patient Population
22 Jul 2021
Contributed by Lukas
Send a textGlobal Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer ...
S2-E37.3 - Spreading the NASH Message Throughout the Broader Community Of Healthcare Practitioners
18 Jul 2021
Contributed by Lukas
Send a textJörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia mar...
S2-E37.2 - NASH Diagnostics Provide a Natural Brake on Overly Broad Adoption of NASH Drugs
17 Jul 2021
Contributed by Lukas
Send a textJörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia mar...
S2-E37.1 - Key Reasons the NASH Drug Market Will Evolve Differently From Statins
17 Jul 2021
Contributed by Lukas
Send a textJörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia mar...
S2-E37 - Why the NASH Market Is Different From Statins
15 Jul 2021
Contributed by Lukas
Send a textJörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia mar...
S2-E36.3 - From the #ILC2021 Wrap-up: Focus on Care Pathways and Treatment Roles
04 Jul 2021
Contributed by Lukas
Send a textQuentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takea...
S2-E36.2 - From The #ILC2021 Wrap-Up: Focus On Drug Development
03 Jul 2021
Contributed by Lukas
Send a textQuentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takea...
S2-E36.1 - From the #ILC2021 Wrap-up: Focus on Diagnostics
03 Jul 2021
Contributed by Lukas
Send a textQuentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takea...
S2-E36 - #ILC2021 Wrap-Up: Big Issues, Key Takeaways, Remaining Issues
01 Jul 2021
Contributed by Lukas
Send a textKey opinion leaders Quentin Anstee, Mazen Noureddin and Ian Rowe join Stephen, Louise and Roger to discuss the major lessons and dangling q...
S2-E35 - #ILC2021 Day Four - Promising Times Ahead, Maybe With a Few More Bumps In the Road
26 Jun 2021
Contributed by Lukas
Send a textDonna Cryer, Vlad Ratziu, Michael Charlton and Mazen Noureddin join Roger Green in reviewing the final day of #ILC 2021.The conversation re...
S2-E34 - #ILC2021 Day Three - Multi-Disciplinary NAFLD Thinking, with Exciting Drugs on the Horizon
25 Jun 2021
Contributed by Lukas
Send a textManal Abdelmalek, Ian Rowe and first-timer Ken Cusi join Louise Campbell and Roger Green to review a thought-provoking, assumption-challeng...
S2-E33 - #ILC2021 Day Two -- Learning About Patients Through Large Databases
24 Jun 2021
Contributed by Lukas
Send a textJörn Schattenberg, Naim Alkhouri, Dr. Michelle Long of Boston University and Livia Alimena of the Global Liver Institute join Roger to rev...
S2-E32 - Leaders Provide Perspectives on #ILC2021
24 Jun 2021
Contributed by Lukas
Send a textIncoming EASL Secretary General Prof. Thomas Berg, Global Liver Institute President and CEO Donna Cryer and Genfit Head of Global Diagnosti...
S2-E31.3 - Previewing Digital ILC 2021 -- Part II -- NITs, late-breakers and intriguing topics
20 Jun 2021
Contributed by Lukas
Send a textJörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green identify specific sessions and presentations they believe will bring ...
S2-E31.2 - Previewing Digital ILC 2021 -- Part II -- Drug Development
19 Jun 2021
Contributed by Lukas
Send a text Stephen Harrison and Jörn Schattenberg discuss what the titles of Digital ILC 2021 presentations tell us about possible findings in drug...
S2-E31.1 - Previewing Digital ILC 2021 -- Part II -- "Favorite Things" and Discussing Metabolic issues
19 Jun 2021
Contributed by Lukas
Send a textJörn Schattenberg and the regular Surfers identify one thing about the Digital ILC 2021 meeting they anticipate eagerly and fall into a di...
S2-E31 - DIgital ILC 2021 -- Preview II
17 Jun 2021
Contributed by Lukas
Send a text Joern Schattenberg joins the Surfers to identify exciting presentations and sessions from the Digital ILC 2021 meeting. Digital ILC 2021...
S2-E30.3 - The Global Liver institute US NASH Action Plan - treatment and health system challenges
13 Jun 2021
Contributed by Lukas
Send a textGlobal Liver Institute Director of Global Policy Andrew Scott, Madrigal Pharmaceuticals Co-Founder and CMO Becky Taub, and Central Virginia...
S2-E30.2 - The Global Liver Institute US NASH Action Plan - Common, Reliable Diagnostics Are Critical
12 Jun 2021
Contributed by Lukas
Send a textGlobal Liver Institute Director of Global Policy Andrew Scott, Madrigal Pharmaceuticals Co-Founder and CMO Becky Taub, and Central Virginia...
S2-E30.1 - The Global Liver Institute US NASH Action Plan - Overview And What Education Must Achieve
12 Jun 2021
Contributed by Lukas
Send a textGlobal Liver Institute Director of Global Policy Andrew Scott, Madrigal Pharmaceuticals Co-Founder and CMO Becky Taub, and Central Virginia...
S2-E30 - The Global Liver institute US NASH Action Plan - What It Is and How We All Can Help Support it
10 Jun 2021
Contributed by Lukas
Send a textGlobal Liver Institute Director of Global Policy Andrew Scott walks a diverse set of stakeholders through the US NASH Action Plan, with spe...
S2-E29.3 - Previewing Digital ILC 2021 -- Part 1 -- What might emerge?
06 Jun 2021
Contributed by Lukas
Send a textEASL Scientific Committee member Luca Valenti joins the Surfers to "crystal ball" potential key outcomes from Digital ILC 2021.Th...
S2-E29.2 - Previewing Digital ILC 2021 -- Part 1 -- Interests and Issues
05 Jun 2021
Contributed by Lukas
Send a textEASL Scientific Committee member Luca Valenti joins the Surfers to discuss some of the issues that will be discussed at Digital ILC 2021.Af...
S2-E29.1 - Previewing Digital ILC 2021 -- Part 1 -- Meeting Overview
05 Jun 2021
Contributed by Lukas
Send a textStephen Harrison and EASL Scientific Committee member Luca Valenti Preview Highlights of the Digital ILC 2021.Luca and Stephen discuss what...
S2-E29 - Previewing Digital ILC 2021 -- Part 1
03 Jun 2021
Contributed by Lukas
Send a textEASL Scientific Organizing Committee member Prof. Luca Valenti joins the Surfers to discuss some of the major NAFLD-related topics we will ...
S2-E27.2 - A Deeper Look At International NASH Day 2021 -- Activities, Future Plans, And Global Liver Institute Growth
29 May 2021
Contributed by Lukas
Send a textGlobal Liver Institute President and CEO Donna Cryer joins the Surfers to discuss International NASH Day 2021. This conversation takes a de...
S2-E27.1 - previewing International nASH day 2021 -- overview of events
29 May 2021
Contributed by Lukas
Send a textGlobal Liver Institute President and CEO Donna Cryer joins the Surfers to discuss International NASH Day 2021. This conversation provides a...
S2 - E28 - SPECIAL EPISODE: What Can We Learn The Aldafermin Discontinuation In F2/F3 NASH?
27 May 2021
Contributed by Lukas
Send a textRoger Green narrates a series of interviews, conversations and viewpoints about NGM Biopharmaceuticals discontinuing its F2/F3 aldafermin p...
S2-E27 - Previewing International NASH Day -- a growing Day of Global Education and Organizing
27 May 2021
Contributed by Lukas
Send a textGlobal Liver Institute President and CEO Donna Cryer joins the Surfers to discuss International NASH Day 2021. Last year's IND had 100...
S2-E26.3 - How much will real-life NASH treatment decisions depend on the specialty of the prescriber?
23 May 2021
Contributed by Lukas
Send a textazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therapy after current Phase 2b and Phase 3 c...
S2-E26.2 - How simply "Vertebrate" will future NASH therapy be?
22 May 2021
Contributed by Lukas
Send a textMazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therpy after current Phase 2b and Phase 3 c...
S2-E26.1 - What will NASH Pharmacotherapy Look Like When we have Multiple Options?
22 May 2021
Contributed by Lukas
Send a textMazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therpy after current Phase 2b and Phase 3 c...
S2-E26 - What Will Treatment Pathways Look Like For NASH Patients?
20 May 2021
Contributed by Lukas
Send a textMazen Noureddin joins the Surfers to explore the issues and needs that will shape treatment guidelines in a world after NASH drugs come to ...
S2-E25.3 (CORRECTED) - Prevalence of NAFLD and NASH 2021 -- An Urgent Call to Action
17 May 2021
Contributed by Lukas
Send a text(This episode has been reposted to include the complete conversation content.)Louise Campbell and Roger Green join co-authors Stephen Harri...
S2-E25.2 (CORRECTED) - Prevalence of NAFLD and NASH 2021 -- Deeper Dive
17 May 2021
Contributed by Lukas
Send a text(This episode has been reposted to include the complete conversation content.) Louise Campbell and Roger Green join co-authors Stephen Harr...
S2-E25.1 (CORRECTED) - Prevalence of NAFLD and NASH 2021 -- Key Findings
17 May 2021
Contributed by Lukas
Send a text(This episode has been reposted to include the complete conversation content.) Stephen Harrison, Naim Alkhouri and first-time guest Prof. S...
S2-E25 - How many Americans Are Living with NAFLD and NASH?
13 May 2021
Contributed by Lukas
Send a textStudy co-authors Stephen Harrison, Naim Alkhouri and Samer Gawrieh suggest that current estimates of NAFLD and NASH populations in the US m...
S2-E24.3 - From The Fourth Global NASH Congress -- How Diagnostics Will Evolve Over The Next Several Years
09 May 2021
Contributed by Lukas
Send a textAfter having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to coni...
S2-E24.2 - From The Fourth Global NASH Congress -- How Treatment WIll Evolve Over The Next Several Years
08 May 2021
Contributed by Lukas
Send a textAfter having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to cons...
S2-E24.1 - From the Fourth Global NASH Congress -- Changing Paradigms and Guidelines
08 May 2021
Contributed by Lukas
Send a textAfter having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to cons...
S2-E24 - Fourth Global NASH Congress -- Wrapping Up
06 May 2021
Contributed by Lukas
Send a textThe SurfingNASH coverage team from the Fourth Global NASH Congress convenes one more time to consider key takeaways from the Congress. Mana...
S2-E23.1 - From the Fourth Global NASH Congress -- Diagnosing Diagnostics
03 May 2021
Contributed by Lukas
Send a textThe SurfingNASH Team has curated over three hours of recordings from the Fourth Global NASH Congress to highlight pieces that discuss the c...
S2-E23 - Wrapping up Day Two of the Fourth Global NASH Congress -- Drugs, lifestyles and Health policy
01 May 2021
Contributed by Lukas
Send a textIan Rowe and GenFit Global Diagnostics Leader Suneil Hosmane join Louise and Roger as they keep discussing Day Two of the 4th Global NASH C...
S2-E22 - Day Two at the 4th Global NASH Congress -- many New Drugs and Non-Pharmacologic Interventions
30 Apr 2021
Contributed by Lukas
Send a textNaim Alkhouri, Ian Rowe and GenFit Global Diagnostics Leader Suneil Hosmane join Louise Campbell and Roger Green to review presentations fr...
S2-E21 - Day One At The 4th Global NASH Congress -- Diagnostics, Drugs And Regulatory Issues
29 Apr 2021
Contributed by Lukas
Send a textManal Abdelmalek, Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review presentations from Day ...
S2-E20.3 - How Can we Best Use NASHmap in Clinical trials and Patient Treatment?
25 Apr 2021
Contributed by Lukas
Send a textThe Surfers explore the impact that NASHmap, the first Machine Learning model that can identify patients likely to have NASH, can have on c...
S2-E20.2 - What Can We Learn about NASH From NASHmap?
24 Apr 2021
Contributed by Lukas
Send a textThe Surfers analyze outputs from NASHmap, the first Machine Learning model that can identify patients likely to have NASH, to learn what we...
S2-E20 - 14-variable Machine Learning model identifies Probable NASH patients from Electronic Health Records
22 Apr 2021
Contributed by Lukas
Send a textJörn Schattenberg discusses NASHmap, the first Machine Learning model that can identify patients likely to have NASH in clinical settings....
S2-E20.1 - How NASHmap, the 1st Machine Learning Model to Identify Probable NASH Patients, Came to Life
21 Apr 2021
Contributed by Lukas
Send a textJörn Schattenberg discusses the issues that drove the project to develop a Machine Learning model that can identify patients likely to hav...
S2-E19.3 - Pharmacotherapy Themes At The 4th Global NASH Congress
18 Apr 2021
Contributed by Lukas
Send a textJörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review pharmacotherapy themes to be covered at t...
S2-E19.2 - Patient-Centric Themes At The 4th Global NASH Congress
17 Apr 2021
Contributed by Lukas
Send a textJörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review holistic and patient-centric issues to be...
S2-E19.1 - Non-Invasive Testing Themes at the 4th Global NASH Congress
17 Apr 2021
Contributed by Lukas
Send a textJörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review non-invasive testing themes to be covered...
S2-E19 - Previewing the 4th Global NASH congress
15 Apr 2021
Contributed by Lukas
Send a textJörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to survey the agenda for the 4th Global NASH Congre...
S2 E18.3 -- Stephen Harrison and Alina Allen discuss what her work portends for future trials.
11 Apr 2021
Contributed by Lukas
Send a textRoger Green conducts one-on-one interviews with Stephen Harrison and Alina Allen to explore specific issues regarding new issues and insigh...
S2 E18.2 -- How Might We Treat Differently If We Knew Which Cirrhotic Patients Are Likely To Progress?
10 Apr 2021
Contributed by Lukas
Send a textThe group focuses on the patient treatment implications of being able to identify the patients who are at risk of rapid progression, partic...
S2 E18.1 -- How Does MR Elastography Help Identify NASH PAtients Who Are Likely To Progress?
10 Apr 2021
Contributed by Lukas
Send a textAlina Allen shares the results of her recent Clinical Gastroenterology and Hepatology paper on predictive value of MR Elastography in deter...
S2-E18 - Magnetic Resonance Elastography Predicts Prognosis for NASH patients
08 Apr 2021
Contributed by Lukas
Send a textAlina Allen of the Mayo Clinic joins the Surfers to discuss her recent publication demonstrating that kPa scores from MR Elastography can p...
S2-E17.3 -- The value of ultrasound and the goals of patient screenin
04 Apr 2021
Contributed by Lukas
Send a textIan Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. This conversat...
S2-E17.2 — Modeling the relative impact of treating NASH vs. CVD in patients with different fibrosis levels
03 Apr 2021
Contributed by Lukas
Send a textIan Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this...
S2-E17.1 - Questions in Screening: Do Liquid Tests Bring Better Value than Elastography?
03 Apr 2021
Contributed by Lukas
Send a textIan Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this...
S2-E17 - New lessons from Leeds: Streamlining Non-Invasive Testing algorithms
01 Apr 2021
Contributed by Lukas
Send a textIan Rowe joins the Surfers to discuss more detailed findings from the on-going analyses he and Richard Parker are conducting on abnormal li...
S2-E16.3 - How NASH treatment Might Evolve as Therapies Come to Market
28 Mar 2021
Contributed by Lukas
Send a textThe final conversation of Episode 16 explores possible possible pathways and treatment strategies for NASH therapy in a future world with m...
S2-E16.2 - Future Directions for NASH Cost-Effectiveness Research
27 Mar 2021
Contributed by Lukas
Send a textMazen Noureddin and Stephen Harrison discuss future directions cost-effectiveness research in and outside the U.S. might take, while the Su...
S2 E16.1 -- How Cost-Effectiveness Research On Widespread NIT Screening In The U.S. Has Evolved
27 Mar 2021
Contributed by Lukas
Send a textMazen Noureddin describes how he became engaged in studying the cost-effectiveness of widespread NASH screening for diabetics in the US, an...
S2-E16 -- Cost-Effectiveness of Widespread Non-Invasive NASH Testing and Treatment
25 Mar 2021
Contributed by Lukas
Send a textMazen Noureddin joins the Surfers to discuss his work determining cost effectiveness of Non-Invasive Testing in Type 2 diabetics and the br...
S2-E15 — Wrapping Up NASH-TAG 2021
18 Mar 2021
Contributed by Lukas
Send a textSurfing the NASH Tsunami closes the book on NASH-TAG 2021 by considering highlights and major themes of the conference. The conversation fo...
S2-E14 - NASH-TAG Session 4 Summary: Basic Science and Promising Drugs on the Horizon
15 Mar 2021
Contributed by Lukas
Send a textNaim Alkhouri and Jörn Schattenberg join Roger and Donna to review the closing session of NASH-TAG 2021, a potpourri of basic science and ...
S2-E13 - NASH-TAG Session 3 Summary: Trial Designs of the Future and the Future of Diabetes Drugs in NASH
14 Mar 2021
Contributed by Lukas
Send a textNASH-TAG Co-director Michael Charlton and Ian Rowe join Roger, Louise and Donna to review the morning that Michael himself identified as on...
S2-E12 - NASH-TAG Session 2 Summary: Innovative Trial Design and Robust Histologic Analyses
13 Mar 2021
Contributed by Lukas
Send a textJörn Schattenberg and Naim Alkhouri join the Surfers (including NASH-TAG co-director Stephen Harrison) to review NASH-TAG session to with ...
S2 E11 — NASH-TAG Session 1 summary: Major Drugs in Development and Why Trials Fail
12 Mar 2021
Contributed by Lukas
Send a textManal Abdelmalek and Ian Rowe join Roger, Louise and Donna to review the morning that Vlad Ratziu and Michael Charlton both identified as t...
S2 E10 — Before NASH-TAG, Conversations With Co-Directors
11 Mar 2021
Contributed by Lukas
Send a textNASH-TAG Co-directors Vlad Ratziu and Michael Charlton talk with Roger Green about the upcoming conference, after which Roger discusses the...
S2-E9.2—Drug-Free Treatment of Early Fatty Liver Disease: Issues for Public Health
07 Mar 2021
Contributed by Lukas
Send a textDonna Cryer joins the Surfers to consider some of the public health issues and implications surrounding treatment of Early Fatty Liver dise...
S2-E9.3 — Introducing LIVErHEALTHY: a program for patients with Early Fatty Liver disease
07 Mar 2021
Contributed by Lukas
Send a textExecutives from Echosens, Chronwell and ModifyHealth join to introduce LIVErHEALTHY, their integrated program for early Fatty Liver disease...
S2-E9.1—Drug-Free Treatment of Early Fatty Liver Disease: Identity matters
07 Mar 2021
Contributed by Lukas
Send a textDonna Cryer and Roger Green lead a conversation of why identity matters for patients trying to resolve fatty liver disease without medicati...
S2-E9 - Novel Approaches to Drug-Free Treatment of Early Fatty Liver Disease
04 Mar 2021
Contributed by Lukas
Send a textDonna Cryer joins the Surfers to discuss the importance of identity in lifestyle modification, after which our sponsors from Echosens prese...
S2-E8.3 - Previewing NASH-TAG 2021: Two intriguing side conversations
27 Feb 2021
Contributed by Lukas
Send a textThis conversation integrates two significant side conversations during the review of the NASH-TAG 2021 agenda, one about creativity and int...
S2-E8.2 - Previewing NASH-TAG 2021: Day Two
27 Feb 2021
Contributed by Lukas
Send a textStephen Harrison previews Day Two of NASH-TAG while Ian Rowe, Louise Campbell, and Roger Green the issues that each of them anticipates mos...
S2-E8.1 - Previewing NASH-TAG 2021: Day One
27 Feb 2021
Contributed by Lukas
Send a textStephen Harrison discusses the history of NASH-TAG and what makes it special while previewing Day One of the 2021 meeting. In this conversa...
S2-E8 - Previewing NASH-TAG 2021
25 Feb 2021
Contributed by Lukas
Send a textStephen Harrison previews NASH-TAG 2021, the pre-eminent NASH drug development meeting, which will take place from March 10-12. This year m...
S2-E7.3 - The newer diabetes drugs and NASH: Educating and Motivating Stakeholders
20 Feb 2021
Contributed by Lukas
Send a textThe panelists consider the barriers to bringing NASH into central consciousness in diabetes therapy and some keys to success.Louise Campbel...
S2-E7.2 - The Newer Diabetes Drugs and NASH: How T2D Patients are likely to respond
20 Feb 2021
Contributed by Lukas
Send a textWayne Eskridge describes some of the opportunities and concerns that affect diabetic patients might experience as they learn about NASH and...
S2-E7.1 - The Newer Diabetes Drugs and NASH: Modes of Action
20 Feb 2021
Contributed by Lukas
Send a textJörn Schattenberg reviews modes of action for GLP-1 agonists and SGLT-2 inhibitors and discusses the data that exist in NAFLD and NASH. Th...
S2-E7 - The Newer Diabetes Drugs and Patients with NASH
18 Feb 2021
Contributed by Lukas
Send a textJörn Schattenberg and Fatty Liver Foundation President Wayne Eskridge join Louise and Roger to consider the current and future roles that ...
S2 E6.3 - #RealTalk: Trial Recruiting Challenges: Traps to Avoid in designing patient protocols for NASH Trials
14 Feb 2021
Contributed by Lukas
Send a textThree experience NASH trial site execs identify at least 11 specific things to consider when designing your trial protocols.Stephen Harriso...
S2 E6.2 - #RealTalk: Trial Recruiting Challenges: Educating Physician during the pandemic
13 Feb 2021
Contributed by Lukas
Send a textThe panel explores three less obvious ways that the COVID-19 pandemic has affected the ability to recruit the right patients into clinical ...
S2 E6.1 - #RealTalk: Trial Recruiting Challenges: Daunting Numbers and Challenging Protocols
13 Feb 2021
Contributed by Lukas
Send a textNaim Alkhouri and Dr. Rashmee Patil of the South Texas Research Institute join the Surfers to discuss misconceptions about the ease of recr...